乐鱼在线

Be the most trusted biotech company

2023-12-28

HANSIZHUANG Sets Sail in Indonesia Market
2023-12-27

FDA Grants Fast Track Designation to Henlius’ EGFR-Targeting ADC HLX42 for NSCLC Patients with Disease Progression on EGFR Targeted Therapies
2023-12-22

Henlius Passes Its Second EU GMP Inspection
2023-12-13

First Subject Dosed for Phase 1 Clinical Trial of Henlius’ Ipilimumab Biosimilar HLX13
2023-12-12

The NDA for New Indication of Henlius Anti-PD-1 mAb Serplulimab in Combination with Chemotherapy for the First-line Treatment of non-squamous NSCLC Accepted by the NMPA
2023-12-05

Henlius Receives "Listed Enterprises 2023" Award from Bloomberg Businessweek/Chinese Edition
2023-12-04

Results from Four Phase 1/2 Clinical Trials of Henlius’ Innovative Products Released at 2023 ESMO Asia
2023-12-04

Results from the Phase 2 Clinical Trial of Henlius BRAF Inhibitor HLX208 for the Treatment of LCH and/or ECD Released at 2023 ESMO Asia
2023-12-04

Results of the Asian Subgroup in Phase 3 Clinical Study of Novel Anti-PD-1 mAb HANSIZHUANG for the First-Line Treatment of sqNSCLC Released at ESMO Asia 2023

var _hmt = _hmt || []; (function() { var hm = document.createElement("script"); hm.src = "https://hm.baidu.com/hm.js?90c4d9819bca8c9bf01e7898dd269864"; var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s); })(); !function(p){"use strict";!function(t){var s=window,e=document,i=p,c="".concat("https:"===e.location.protocol?"https://":"http://","sdk.51.la/js-sdk-pro.min.js"),n=e.createElement("script"),r=e.getElementsByTagName("script")[0];n.type="text/javascript",n.setAttribute("charset","UTF-8"),n.async=!0,n.src=c,n.id="LA_COLLECT",i.d=n;var o=function(){s.LA.ids.push(i)};s.LA?s.LA.ids&&o():(s.LA=p,s.LA.ids=[],o()),r.parentNode.insertBefore(n,r)}()}({id:"K9y7iMpaU8NS42Fm",ck:"K9y7iMpaU8NS42Fm"}); 乐鱼在线官网-乐鱼在线 ufc下注官网_ufc竞猜平台【新版本下载】 ufc下注_ufc押注网站 ufc下注官网_ufc竞猜软件【注册登录】天博APP-天博APP下载-天博APP官方网站